Auspicious Laboratory INC.

Auspicious Laboratory INC. was paid $1.88M by Medicaid between Jan 2018 and Dec 2024, across 52 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 26% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Texas

Rank by total paid#46 of 436

Median peer was paid$17K

This provider vs. median109×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	2,275	$5K
2019	4,029	$42K
2020	20,310	$409K
2021	45,649	$607K
2022	23,781	$321K
2023	19,685	$236K
2024incomplete	20,397	$257K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	26%	9,435	8,788	$494K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	10%	2,302	2,087	$195K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	10%	1,328	1,289	$191K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	8.6%	11,050	10,279	$161K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	5.4%	6,787	6,289	$101K
87631		3.7%	1,170	1,075	$69K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	3.3%	3,393	2,623	$63K
80336		2.7%	5,929	5,376	$51K
87581		2.0%	2,500	2,365	$38K
87486		2.0%	2,500	2,365	$38K
80338		1.8%	5,905	5,354	$34K
80355		1.3%	5,910	5,359	$25K

40 more codes

80321		1.3%	4,551	$24K
80363		1.3%	2,743	$24K
82575		1.3%	6,060	$24K
80366		1.2%	5,943	$23K
80361		1.0%	2,583	$19K
80348		1.0%	2,625	$19K
80346		1.0%	2,637	$19K
80349		<1%	2,599	$18K
80356		<1%	2,624	$18K
80354		<1%	2,625	$18K
80324		<1%	2,637	$17K
80365		<1%	2,625	$17K
80370		<1%	2,938	$16K
80367		<1%	2,919	$16K
80357		<1%	2,910	$16K
80358		<1%	2,627	$15K
80373		<1%	2,945	$15K
80372		<1%	2,947	$15K
80368		<1%	2,868	$14K
80353		<1%	2,626	$13K
80359		<1%	2,636	$13K
80360		<1%	2,244	$12K
83992		<1%	1,564	$12K
80345		<1%	1,141	$6K
87481		<1%	546	$3K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	<1%	5,536	$3K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	121	$2K
87426	Infectious agent antigen detection, SARS-CoV-2 (COVID-19)	<1%	48	$1K
86769		<1%	35	$1K
87640		<1%	252	$1K
87500		<1%	239	$960.50
87186		<1%	242	$604.52
87653		<1%	34	$287.49
87265		<1%	109	$248.60
80320		<1%	19	$70.65
80337		<1%	19	$65.25
99000		<1%	45	$10.80
80364		0%	19	$0.00
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	0%	17	$0.00
80184		0%	19	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialPUROHIT, SIKHA (BILLING & A/R MANAGER)